Psychopharmacology of anxiety disorders
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Exposure of the general population to a 1:4 lifetime risk of disabling anxiety has inspired generations of fundamental and clinical psychopharmacologists, from the era of the earliest benzodiazepines (BZ) to that of the selective serotonin reuptake inhibitors (SSRIs) and related compounds, eg, the serotonin and norepinephrine reuptake inhibitors (SNRIs). This comprehensive practical review summarizes current therapeutic research across the spectrum of individual disorders: generalized anxiety disorder (GAD), panic disorder (PD) and agoraphobia (social anxiety disorder), compulsive disorder (OCD), phobic disorder (including social phobia), and posttraumatic stress disorder (PTSD). Specific diagnosis is a precondition to successful therapy: despite substantial overlap, each disorder responds preferentially to specific pharmacotherapy. Comorbidity with depression is common; hence the success of the SSRIs, which were originally designed to treat depression. Assessment (multidomain measures versus individual end points) remains problematic, as-frequently-do efficacy and tolerability The ideal anxiolytic remains the Holy Grail of worldwide psychopharmacologic research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multicenter Collaborative Panic Disorder Severity Scale
Shear, M. K., Brown, T. A., Barlow, D. H., Money, R., Sholomskas, D. E., Woods, S. W., Gorman, J. M., & Papp, L. A. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.11.1571 · Cited by 1,001 · cited 2×
“Although there are different responses of each of these symptoms to these treatments (eg, agoraphobic avoidance is the most difficult to treat), successful treatments effectively reduce all these aspects of the PD syndrome, but appropriate outcome measures for PD still remain a problem.(64) Reduction of panic-attack f…”
BackgroundMethodPilot study of secondary prevention of posttraumatic stress disorder with propranolol
Pitman, R. K., Sanders, K. M., Zusman, R. M., Healy, A. R., Cheema, F., Lasko, N. B., Cahill, L., & Orr, S. P. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01279-3 · Cited by 964
Cognitive Behavioral Group Therapy vs Phenelzine Therapy for Social Phobia: 12-Week Outcome
Heimberg, R. G., Liebowitz, M. R., Hope, D. A., Schneier, F. R., Holt, C. S., Welkowitz, L. A., Juster, H. R., Campeas, R., Bruch, M. A., Cloitre, M., et al. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1133 · Cited by 585
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571
Ballenger, J. C. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800290027004 · Cited by 564
Phenelzine vs Atenolol in Social Phobia: A Placebo-Controlled Comparison
Liebowitz, M. R., Schneier, F., Campeas, R., Hollander, E., Hatterer, J., Fyer, A., Gorman, J., Papp, L., Davies, S., Gully, R., et al. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.49.4.290 · Cited by 444 · cited 1×
“Also the β-blocker atenolol, despite early promise, proved ineffective when tested in patient populations with generalized symptoms of social phobia.(90,118) Pindolol was no more effective than placebo in augmenting the effects of paroxetine treatment for generalized social phobia.”
BackgroundCognitive-Behavioral and Pharmacological Treatments of Social Phobia: A Controlled Study
Gelernter, C. S. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810340070009 · Cited by 404
(1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.12.1521 · Cited by 301 · cited 1×
“Limited available evidence suggests that when effective pharmacotherapy is discontinued, most patients (90%) do relapse.(168) Therefore, current practice is to continue effective pharmacotherapy for at least 1 to 2 years or indefinitely.”
BackgroundBehavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis
Kobak, K. A., Greist, J. H., Jefferson, J. W., Katzelnick, D. J., & Henk, H. J. (1998) · Psychopharmacology · doi:10.1007/s002130050558 · Cited by 276
Long-term Diazepam Therapy and Clinical Outcome
Rickels, K. (1983) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.250.6.767 · Cited by 276
Cited by
Neurobiology of fear and specific phobias
Garcia, R. (2017) · Learning & Memory · doi:10.1101/lm.044115.116 · Cited by 239
“First, as previously mentioned, SSRI, by increasing concentrations of 5-HT in the synapse cleft, have been found effective for phobias (Cassano et al. 2002).”
BackgroundAnxious to see you: Neuroendocrine mechanisms of social vigilance and anxiety during adolescence
Wright, E. C., Hostinar, C. E., & Trainor, B. C. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14628 · Cited by 55
Sexual differentiation of neural mechanisms of stress sensitivity during puberty
Wright, E. C., Luo, P. X., Zakharenkov, H. C., Serna Godoy, A., Lake, A. A., Prince, Z. D., Sekar, S., Culkin, H. I., Ramirez, A. V., Dwyer, T., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2306475120 · Cited by 40
Enhanced activity of pyramidal neurons in the infralimbic cortex drives anxiety behavior
Berg, L., Eckardt, J., & Masseck, O. A. (2019) · PLOS ONE · doi:10.1371/journal.pone.0210949 · Cited by 38
Tran, L., Sharrad, K., Kopsaftis, Z., Stallman, H. M., Tai, A., Spurrier, N., Esterman, A., & Carson-Chahhoud, K. (2021) · Journal of Asthma · doi:10.1080/02770903.2020.1731826 · Cited by 22
Metadata
- Authors
- Cassano, G. B., Rossi, N. B., & Pini, S.
- Venue
- Dialogues in Clinical Neuroscience
- Publisher
- Informa UK Limited
- Published
- 2002-09-30
- Volume
- 4
- Issue
- 3
- Pages
- 271-285
- ISSN
- 1294-8322 (ISSN-L)
- 1958-5969
- OpenAlex
- W4292963246
- Cited by
- 63
- References
- 18
- FWCI
- 0.48
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Psychopharmacology of anxiety disorders. https://app.cochat.ai/papers/10.31887/dcns.2002.4.3/gcassano
- The paper
- Cassano, G. B., Rossi, N. B., & Pini, S. (2002). Psychopharmacology of anxiety disorders. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2002.4.3/gcassano
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.